Keystone Investors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Keystone Investors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$3.53M	Buy	+8,880	New	+$3.93M	0.32%	46

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Keystone Investors's ALNY Position: Q4 2025 in Review

Keystone Investors opened a new position in Alnylam Pharmaceuticals (ALNY) in Q4 2025: 8,880 shares worth $3.53M. The stake represents 0.32% of the portfolio and ranks #46 among its holdings.

851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

Keystone Investors held 8,880 shares of Alnylam Pharmaceuticals worth $3.53M as of Q4 2025.
Alnylam Pharmaceuticals was a new Keystone Investors position in Q4 2025.
Alnylam Pharmaceuticals made up 0.32% of Keystone Investors's portfolio in Q4 2025, its #46 holding.
851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Keystone Investors's 13F filing for Q4 2025, filed 13 Feb 2026.